Bifunctional BTK PROTACs for Targeted BTK Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current BTK inhibitors are not potent enough and lack effective alternative strategies for degrading BTK, which are crucial for treating autoimmune and inflammatory diseases.
Innovation Solution
Development of bifunctional compounds that conjugate BTK inhibitor moieties with E3 ligase ligands to recruit targeted proteins for degradation via the ubiquitin-proteasome pathway, utilizing novel PROTAC technology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional BTK inhibitors are used, then BTK activity is inhibited, but the potency is insufficient and degradation is not achieved
Solution Approach 1:
The bifunctional compound is divided into two distinct functional segments: a BTK inhibitor moiety (first functional group) and an E3 ligase ligand moiety (second functional group). This segmentation allows each segment to independently perform its specific function - inhibiting BTK activity and recruiting E3 ligase respectively - thereby achieving both potent inhibition and degradation capability that conventional single-function inhibitors cannot provide
Solution Approach 2:
The bifunctional compound integrates multiple functions into a single molecular entity: it simultaneously acts as a BTK inhibitor, an E3 ligase ligand, and a PROTAC degrader. This multi-functionality enables the compound to not only inhibit BTK activity but also recruit E3 ligase to facilitate BTK degradation, overcoming the limitation of conventional inhibitors that lack degradation capability
2Reliability
If PROTAC technology is used to degrade BTK, then degradation is achieved, but compound complexity increases
Solution Approach 1:
The patent merges the BTK inhibitor function and E3 ligase ligand function into a single integrated bifunctional compound structure. By combining these two functional groups in one molecule, the patent achieves BTK degradation through PROTAC mechanism while avoiding the need for separate compounds or complex multi-step systems, thus managing complexity through functional integration
3Reliability
If existing E3 ligase ligands are used, then protein degradation is induced, but specificity for BTK is insufficient
Solution Approach 1:
The E3 ligase ligand moiety in the bifunctional compound is specifically designed with structural features that confer high affinity and specificity for BTK. The ligand portion contains specific molecular recognition elements that selectively bind to BTK's unique structural characteristics, ensuring precise targeting and degradation of BTK while minimizing off-target effects on other proteins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the potency of BTK inhibition by promoting its degradation, offering potential therapeutic benefits for autoimmune and inflammatory diseases.
Implementation Method 1
PROTAC utilizes the ubiquitin-protease system to target a specific protein and induce its degradation in the cell
Implementation Method 2
Ubiquitin, which is highly conserved in eukaryotic cells, is a modifier molecule, composed of 76 amino acids, that covalently binds to and labels target substrates via a cascade of enzymatic reactions involving E1, E2, and E3 enzymes
Data Source
AI summary
Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.